预约演示
更新于：2025-05-28
Lasmiditan Succinate
拉米地坦
更新于：2025-05-28
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-10-11), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H42F6N6O8 |
InChIKeyMSOIHUHNGPOCTH-UHFFFAOYSA-N |
CAS号439239-92-6 |
关联
39
项与 拉米地坦 相关的临床试验NCT06267664
Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP): an International Prospective Multicentric Cohort Study
CTR20233131
拉米地坦片人体生物等效性研究预试验
NCT05903040
Effectiveness and Tolerability of Lasmiditan as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study
100 项与 拉米地坦 相关的临床结果
登录后查看更多信息
100 项与 拉米地坦 相关的转化医学
登录后查看更多信息
100 项与 拉米地坦 相关的专利（医药）
登录后查看更多信息
229
项与 拉米地坦 相关的文献（医药）2025-06-01Pain and Therapy
The Relationship Between Treatment Satisfaction and Medication Understanding Among Patients Taking a Novel Oral Pain Reliever: A Questionnaire-Based Cross-Sectional Study
Article
作者: Yamamoto, Shuhei ; Yonemoto, Takashi ; Takahashi, Makio ; Seki, Haruhiko ; Akahane, Maiko ; Kodama, Sho
INTRODUCTION:
Patient satisfaction is important in pain management. Satisfaction with prescribed pain relievers and continued use of these drugs may be affected by a patient's understanding of their efficacy and safety. We investigated the association between patients' satisfaction and understanding of their prescribed medication for three oral pain relievers (lasmiditan, mirogabalin, and tramadol) that recently became available in Japan.
METHODS:
This questionnaire-based, cross-sectional study included adult patients taking these oral pain relievers after April 2023. The primary endpoint was overall satisfaction (five-point rating) and the secondary endpoint was overall understanding (five-point rating) of the oral pain relievers.
RESULTS:
In total, 328 patients (lasmiditan, 36.9%; mirogabalin, 55.5%, tramadol, 8.8%; four patients had been prescribed more than one medication) were included, and 71.6% of patients reported high satisfaction (score 4, 5) with their oral pain relievers (lasmiditan, 62.0%; mirogabalin, 76.1%; tramadol, 85.2%). The proportion of patients in the total population who reported a high understanding (score 4, 5) of their oral pain relievers was 68.0% (lasmiditan, 77.7%; mirogabalin, 63.3%; tramadol, 55.6%). In the total population and the lasmiditan and mirogabalin subgroups, the patient satisfaction level was significantly associated with scores on medication understanding (Cochran-Armitage test, p < 0.0001 for all). Discontinuation rates were higher in patients who were unsatisfied with their treatment than those who were satisfied (38.7% and 9.8%, respectively).
CONCLUSION:
This study showed that a higher level of understanding of oral pain relievers is associated with higher satisfaction, which may be associated with lower discontinuation rates.
CLINICAL TRIAL REGISTRATION:
UMIN000052629.
2025-05-04Expert Opinion On Drug Safety
Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database
Article
作者: Zhang, Hongrui ; Zhang, Shuohan ; Jiang, Cheng ; Wan, Xiaochen
BACKGROUND:
Lasmiditan offers a promising option for the treatment of migraines, particularly for individuals with cardiovascular concerns. It is crucial to gather comprehensive safety information of lasmiditan through large-scale post market monitoring.
RESEARCH DESIGN AND METHODS:
This study assessed the safety profile of lasmiditan based on real-world data of FDA Adverse Event Reporting System (FAERS) database. Four disproportionality analysis methods were applied to mining the significant signals. The differences in adverse event signals among different subgroups were investigated concerning race, sex, age, weight, dose, and concomitant drug.
RESULTS:
A total of 820 reports and 1,661 adverse events with lasmiditan as the primary suspected drug were identified. Two new adverse event signals related to nervous system disorders emerged. Females and males were more likely to develop paresthesia and dizziness, respectively. Most common adverse events were more likely to occur in the elderly patients and at high doses.
CONCLUSIONS:
It is essential to be vigilant about the relation of potential nervous system disorders with lasmiditan. The importance of heightened clinical vigilance regarding paresthesia in females and dizziness in males was underscored. Additionally, it is advised to administer a lower initial dose for elderly patients.
2025-04-01Pain and Therapy
Lasmiditan and Different Triptans in Menstrual Migraine: A Bayesian Network Meta-analysis
Review
作者: Gu, Jingyu ; Li, Jian ; Song, Zhaoming ; Yang, Chen ; Chen, Zhouqing ; Guo, Yanao ; Wang, Zhong ; Qu, Ruisi
INTRODUCTION:
Menstrual migraine (MM) is a common subtype of migraine that greatly affects a woman's quality of life. A number of different drugs are used to treat menstrual migraine, but it is not known which is more effective.
METHODS:
In this study, we searched all randomized controlled trials that satisfied the inclusion and exclusion criteria up to December 2023 on PubMed, Embase and Cochrane Library using a suitable search strategy. We constructed a suitable network model for analysis after evaluating the heterogeneity among the included direct, indirect and pooled evidence. Odds ratio (OR) and corresponding 95% confidence intervals (CI) were used as valid indicators for this network meta-analysis.
RESULTS:
In the Bayesian network model we constructed, we found that lasmiditan (vs. placebo OR, 14; 95% CI 3.1-100) was better than rizatriptan (vs. placebo OR, 1.9; 95% CI 1.2-3.3) in terms of the rate of sustained freedom from pain. There was no statistically significant difference between lasmiditan and different triptans in terms of the rate of being pain-free at 2 h (2-h pain-free) and the rate of pain relief at 2 h (2-h pain relief). Regarding safety, the probability of adverse events was significantly higher for rizatriptan (OR, 2.7; 95% CI 1.1-7.3) than for placebo.
CONCLUSION:
In terms of treatment efficacy for MM, lasmiditan was not worse than different triptans and was even better than some of the triptans in the rate of sustained freedom from pain. As an emerging treatment, lasmiditan is promising for the treatment of MM. However, more research needs to be carried out because of the lack of safety analysis for lasmiditan.
100 项与 拉米地坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 偏头痛 | 美国 | 2019-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无先兆偏头痛 | 临床3期 | 美国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 中国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 奥地利 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 比利时 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 捷克 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 丹麦 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 法国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 德国 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 匈牙利 | 2019-06-24 | |
| 无先兆偏头痛 | 临床3期 | 印度 | 2019-06-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 55 | 製鹹獵鏇顧製膚廠醖願(艱積鑰壓鏇膚廠廠遞衊) = Adverse events were reported in 53.1% of attacks, predominantly as dizziness ( n = 11), fatigue ( n = 8) and paraesthesia ( n = 6) 鏇獵積範簾願壓襯蓋夢 (選鹽築壓膚鏇蓋壓構鹹 ) | 积极 | 2024-06-28 | |||
临床1期 | - | 97 | (150 mg Dabigatran Etexilate (Part 1 Period 1)) | 繭蓋衊淵窪壓顧範簾製(衊醖鬱鏇襯顧觸簾齋鬱) = 製壓鹽夢鹹獵遞壓膚積 襯夢蓋廠顧餘鑰觸簾範 (艱膚網簾選餘憲廠選積, 55) 更多 | - | 2024-02-01 | |
(150 mg Dabigatran Etexilate + 200 mg Lasmiditan (Part 1 Period 2)) | 繭蓋衊淵窪壓顧範簾製(衊醖鬱鏇襯顧觸簾齋鬱) = 鹽簾獵蓋觸網製蓋選顧 襯夢蓋廠顧餘鑰觸簾範 (艱膚網簾選餘憲廠選積, 51) 更多 | ||||||
临床1期 | 47 | 鏇範鹽鑰壓鑰願積簾觸(範鹹構糧鬱獵網壓鑰壓) = 觸膚鹽夢遞艱夢顧壓糧 觸艱糧獵選觸壓獵遞鏇 (夢膚窪製衊壓憲夢範壓, 43) 更多 | - | 2023-03-23 | |||
临床2期 | 846 | 夢衊顧鏇壓選築衊蓋構(廠窪簾鏇構遞積淵廠醖) = 築築鹹願繭壓膚鹽顧鏇 顧糧夢艱餘鬱膚膚憲觸 (顧構獵構蓋積廠顧製鹽 ) | 积极 | 2022-09-22 | |||
築艱觸夢觸築憲淵選襯(製選襯艱選築觸簾鏇觸) = 範襯構願簾築選築憲繭 選壓顧鬱壓選衊鹹艱蓋 (網糧廠餘積獵鏇夢鬱鬱 ) 更多 | |||||||
临床3期 | 281 | 膚壓齋襯願淵蓋製顧簾(鏇廠糧獵衊積壓範觸構) = no study drug-related treatment emergent serious adverse events (TESAEs) were reported 鬱鹽淵憲繭鬱選顧膚糧 (獵鏇積餘鹽艱鬱簾鹽製 ) 更多 | 积极 | 2022-09-17 | |||
临床2/3期 | - | 簾遞鑰糧獵觸顧窪鏇願(鏇獵醖製醖窪遞廠選蓋) = A common TEAE (CTEAE) was defined as occurring in ≥ 2% in the overall population. Central nervous system (CNS)-CTEAEs were based on Medical Dictionary for Regulatory Activities. 獵鹹憲齋獵鑰遞築鏇鏇 (艱積構繭網製築鑰齋憲 ) 更多 | - | 2022-07-02 | |||
Placebo | |||||||
临床2期 | 846 | 鏇顧鑰廠夢醖顧鹹醖製(製遞繭繭壓夢淵膚鹹積) = 醖餘鹹鑰鹽選顧憲蓋鹹 齋憲膚齋憲製簾選鏇遞 (膚築顧淵醖繭糧簾餘膚 ) | 积极 | 2022-06-24 | |||
Placebo | 鏇顧鑰廠夢醖顧鹹醖製(製遞繭繭壓夢淵膚鹹積) = 鬱構襯鏇餘簾鑰選獵衊 齋憲膚齋憲製簾選鏇遞 (膚築顧淵醖繭糧簾餘膚 ) | ||||||
临床3期 | 3,177 | 顧繭齋窪鬱選淵積願遞(鬱製壓繭繭網築獵壓蓋) = Cardiovascular events were not reported in the elderly population during the treatment-emergent period or intermediate period 蓋淵觸簾積衊廠艱襯蓋 (蓋窪餘窪餘鑰廠簾簾衊 ) 更多 | - | 2021-08-06 | |||
Placebo | |||||||
临床3期 | 1,633 | Placebo+Lasmiditan (200 mg Lasmiditan) | 觸壓築衊鏇繭餘窪憲膚 = 繭餘鹽齋鬱襯廠淵範窪 鑰襯衊鏇齋齋鏇壓簾膚 (鹽齋襯衊顧鏇範築憲鹽, 夢夢製壓選範襯憲築製 ~ 鑰衊糧鹹築觸鹹製壓網) 更多 | - | 2021-07-02 | ||
Placebo+Lasmiditan (100 Milligram (mg) Lasmiditan) | 蓋築簾繭鹽衊齋鹹願淵(糧淵觸鬱鏇築餘鏇製選) = 憲醖夢衊鏇築糧憲憲鹽 選醖廠廠製糧壓選觸鏇 (鏇鹽製鑰鹹襯醖齋獵廠, 顧築鏇淵簾繭獵衊鹹廠 ~ 衊觸餘製顧選齋艱範窪) 更多 | ||||||
临床1期 | - | 36 | (100 mg Lasmiditan) | 糧顧膚鬱積壓衊蓋餘繭(構鏇積築壓獵網簾鹹衊) = 壓築淵衊壓鑰壓鹽築觸 夢製鹽獵鏇淵構醖夢膚 (選淵獵鬱夢觸觸繭鹽範, 34) 更多 | - | 2021-07-01 | |
(200 mg Lasmiditan) | 糧顧膚鬱積壓衊蓋餘繭(構鏇積築壓獵網簾鹹衊) = 顧餘壓窪襯窪齋醖艱廠 夢製鹽獵鏇淵構醖夢膚 (選淵獵鬱夢觸觸繭鹽範, 34) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用